Physician profile
Fred H Petty
NPI 1841291333
$1,529.26
in general payments reported to CMS, 2019-2025
21 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $68.58 · 2021: $78.92 · 2022: $271 · 2023: $473 · 2024: $275 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $248.18 | 2021-2025 | |
| Pfizer INC. | $243.53 | 2019-2025 | |
| Esperion Therapeutics, INC. | $179.76 | 2020-2025 | Nexletol |
| Amgen INC. | $135.14 | 2019-2023 | Repatha |
| Alnylam Pharmaceuticals INC. | $122.38 | 2022-2025 | Onpattro |
| Irhythm Technologies, INC. | $120.76 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Baxter Healthcare | $80.71 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Cvrx, INC. | $70.53 | 2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $58.68 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $38.22 | 2024-2025 | Eliquis, Camzyos |
| Abiomed | $27.18 | 2022-2025 | |
| Shockwave Medical, INC | $26.60 | 2022 | |
| Boston Scientific Corporation | $24.29 | 2025 | Bodyguardian |
| Abbott Laboratories | $24.15 | 2025 | Cardiomems |
| Kestra Medical Technology Services, INC. | $22.71 | 2023 | Assure Wcd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $21.23 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $21.21 | 2022 | |
| Medtronic, INC. | $17.82 | 2024 | Linq II |
| Novo Nordisk INC | $16.47 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $15.96 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.